10. The antibody of any of claims 6-9, further comprising a second therapeutic agent.

11. The antibody of any of claims 6-10, wherein said antibody is formulated for administration by a parenteral route, intravenous route or subcutaneous route of administration.

12. Use of an antibody of any claims 1-5 in the manufacture of a medicament for the treatment or amelioration of a disease or disorder selected from the group consisting of: graft v. host disease, autoimmune or inflammatory disease, and CD40-related disorder.

13. The use of claim 12, wherein the autoimmune or inflammatory disease is selected from the group consisting of rheumatoid arthritis, multiple sclerosis, proliferative lupus glomerulonephritis, inflammatory bowel disease (IBD), psoriasis, idiopathic thrombocytopenic purpura (ITP), Crohn's Disease and systemic lupus erythematosus (SLE), Hashimoto's thyroiditis, primary myxoedema, thyrotoxicosis/Graves disease, pernicious anaemia, autoimmune atrophic gastritis, autoimmune carditis, Addison's disease, premature menopause, type 1-diabetes mellitus, Good—pasture's syndrome, myasthenia gravis, autoimmune haemolytic anaemia, idiopathic leucopenia, primary biliary cirrhosis, active chronic hepatitis (HBs Ag negative), cryptogenic cirrhosis, Sjogren's syndrome, dermatomyositis, scleroderma, mixed tissues connective disease, discoid lupus erythematosus, and systemic vasculitis.

14. A pharmaceutical composition comprising: (i) the antibody of any of claims 1-5; and (ii) a pharmaceutically acceptable excipient; and wherein the antibody or antigen binding fragment thereof is optionally conjugated to a second agent.

15. An isolated polynucleotide or polynucleotides encoding:

light chain SEQ ID NO:26 with one of heavy chain SEQ ID NOs 27-30 (Antibody A);

light chain SEQ ID NO:31 with one of heavy chain SEQ ID NOs 32-35 (Antibody B);

light chain SEQ ID NO:36 with one of heavy chain SEQ ID NOs 37-40 (Antibody C);

variable heavy and variable light chain of SEQ ID NOs 44/43 (antibody A);

variable heavy and variable light chain of SEQ ID NOs 53/52 (antibody B); or

variable heavy and variable light chain of SEQ ID NOs 58/56 (antibody C).

~~a heavy chain variable region amino acid sequence and a light chain variable region, wherein the heavy chain variable region amino acid sequence comprises any of SEQ ID NO: 1 to 4, SEQ ID NO:27, SEQ ID NO:28, SEQ ID NO: 29, SEQ ID NO:30, SEQ ID NO:32, SEQ ID NO:33, SEQ ID NO:34, SEQ ID NO:35, SEQ ID NO:37, SEQ ID NO:38, SEQ ID NO:39, SEQ ID NO: 40, SEQ ID NO: 42, SEQ ID NO: 44, SEQ ID NO: 46, SEQ ID NO: 48, SEQ ID. NO. 50, SEQ ID NO: 53, SEQ ID NO: 57, SEQ ID NO: 58, SEQ ID NO: 59, SEQ ID NO: 60, SEQ ID NO: 61, SEQ ID NO: 62, SEQ ID NO: 63, SEQ ID NO: 64, SEQ ID NO: 65, SEQ ID NO: 66, SEQ ID NO: 67, SEQ ID NO: 68, SEQ ID NO: 69, SEQ ID NO: 70, SEQ ID NO: 71, SEQ ID NO: 72, or SEQ ID NO: 73; and light chain variable region amino acid sequence comprises any of SEQ ID NO: 5 to SEQ ID NO:8, SEQ ID NO:26, SEQ ID NO:31, SEQ ID NO:36, SEQ ID NO:41, SEQ ID NO:43, SEQ ID NO:45, SEQ ID NO:47, SEQ ID NO:49, SEQ ID NO:50, SEQ ID NO:51, SEQ ID NO:52, SEQ ID NO:54, SEQ ID NO:55, SEQ ID NO:56, SEQ ID NO:74, SEQ ID NO:75, or SEQ ID NO:76.~~